AWE
CLVS

Avidian Wealth Enterprises’s Clovis Oncology, Inc. CLVS Stock Holding History

Avidian Wealth Enterprises’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-75,000
Closed -$360K – 408
2020
Q4 		$360K Buy
75,000
+9,000
+14% +$45.5K 0.03% 232
2020
Q3 		$385K Buy
+66,000
New +$395K 0.04% 188

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Avidian Wealth Enterprises's CLVS Position: Q1 2021 in Review

Avidian Wealth Enterprises sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 75,000 shares — an estimated $360K sold.

Avidian Wealth Enterprises first reported a position in CLVS in Q3 2020 and held it in 2 quarters. The position peaked at $385K in Q3 2020. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

  • Avidian Wealth Enterprises reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
  • Avidian Wealth Enterprises sold 75,000 Clovis Oncology, Inc. shares in Q1 2021, an estimated $360K.
  • Avidian Wealth Enterprises first reported a position in Clovis Oncology, Inc. in Q3 2020 and held it in 2 quarters.
  • Avidian Wealth Enterprises's Clovis Oncology, Inc. position peaked at $385K in Q3 2020.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on Avidian Wealth Enterprises's 13F filing for Q1 2021, filed 5 May 2021.